{"id":"W4237067208","doi":"10.1200/jco.2020.38.6_suppl.tps600","title":"PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring <i>FGFR3</i> alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Tolerability; Cisplatin; Internal medicine; Oncology; Placebo; Adjuvant therapy; Urology; Cancer; Gastroenterology; Clinical trial; Chemotherapy; Surgery; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001468109,0.001990145,0.002917215,0.0003661631,0.000354225,0.001074572,0.001034526,0.001660394,0.007804209],"category_scores_gemma":[0.001449147,0.0006686957,0.001546359,0.0003517512,0.0009757144,0.001242264,0.0003928085,0.002634632,0.001415017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006190576,"about_ca_system_score_gemma":0.001509301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007977947,"about_ca_topic_score_gemma":0.002046932,"domain_scores_codex":[0.9995868,0.0001908783,0.0000273783,0.00009329183,0.00003631764,0.00006536958],"domain_scores_gemma":[0.9994538,0.0001191628,0.0001368023,0.00003891934,0.00004938367,0.0002019387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9753011,0.005628392,0.0002277517,0.00122667,0.0005780531,0.00003836381,0.00004104954,0.0002786454,0.004134123,0.0001811016,0.001332716,0.01103194],"study_design_scores_gemma":[0.9602376,0.03811648,0.0003856687,0.00002474908,0.0001561851,0.00003121998,0.00001237028,0.0002040209,0.0002322843,0.0001068038,0.0004835252,0.000009181337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9566917,0.01144538,0.001579356,0.001726451,0.001751666,0.01669055,0.004185239,0.0006225465,0.005307074],"genre_scores_gemma":[0.9625223,0.005489948,0.003381452,0.002608774,0.0005203077,0.01565342,0.003404871,0.00006634138,0.006352568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007804209,"threshold_uncertainty_score":0.02610773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0960230797781937,"score_gpt":0.4147880113532452,"score_spread":0.3187649315750515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}